Skip to main content
. Author manuscript; available in PMC: 2019 Jan 15.
Published in final edited form as: Clin Cancer Res. 2017 Nov 7;24(2):306–315. doi: 10.1158/1078-0432.CCR-17-1100

Table 2.

Reasons for Discontinuation

Reason Control Low-dose High-dose Total
Disease progression 3 7 5 15
Withdrew consent 3 5 4 12
Toxicity 0 0 1 1
Comorbidities 2 2 2 6
Othera 3 7 5 15

All reasons given for stopping treatment prior to 12 cycles.

a

Other reasons: rising PSA not meeting protocol defined progression (Control:2, Low:5, High:2), 4 disenrolled before treatment (Control:1, Low:1, High:2), patient stopped taking study drug (High:1), patient transferred to another facility (Low:1)